Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 349-417

  Qiu, Jia Xuan ^a,b   Zhou, Zhi Wei ^c,d   He, Zhi Xu ^d   Zhao, Ruan Jin ^e   Zhang, Xueji ^f   Yang, Lun ^g   Zhou, Shu Feng ^c,d   Mao, Zong Fu ^a  

^a WUHAN UNIVERSITY   (China)

^b NANCHANG UNIVERSITY   (China)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d GUIZHOU MEDICAL UNIVERSITY   (China)

^e Center for Traditional Chinese Medicine   (United States)

^f UNIVERSITY OF SCIENCE AND TECHNOLOGY BEIJING   (China)

^g SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

EMT; Proteomics; SILAC

Indexed keywords

ACETYLCHOLINESTERASE; ACID PHOSPHATASE PROSTATE ISOENZYME; ALPHA GALACTOSIDASE; ANDROGEN RECEPTOR; ARGININOSUCCINATE SYNTHASE; AURORA A KINASE; B RAF KINASE; BLOOD CLOTTING FACTOR 9; CARBONATE DEHYDRATASE IV; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DIHYDROFOLATE REDUCTASE; ESTROGEN RECEPTOR BETA; GLUCOCORTICOID RECEPTOR; GLUTATHIONE SYNTHASE; GLYCINE AMIDINOTRANSFERASE; GLYCOGEN SYNTHASE KINASE 3BETA; JANUS KINASE 2; MACROPHAGE MIGRATION INHIBITION FACTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 10; NICOTINAMIDE METHYLTRANSFERASE; OSTEOGENIC PROTEIN 1; PHENYLALANINE 4 MONOOXYGENASE; PLUMBAGIN; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; STROMELYSIN; UNINDEXED DRUG; URIDINE DIPHOSPHATE GLUCOSE 4 EPIMERASE; ANTINEOPLASTIC AGENT; NAPHTHOQUINONE; TUMOR MARKER; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BIOINFORMATICS; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG RESPONSE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IMMUNITY; MALE; OXIDATION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; STRAIN DIFFERENCE; BINDING SITE; BIOLOGY; CELL CYCLE; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MOLECULAR DOCKING; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; REPRODUCIBILITY; STRUCTURE ACTIVITY RELATION; TIME FACTOR; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; AUTOPHAGY; BINDING SITES; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MALE; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; NAPHTHOQUINONES; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTEIN CONFORMATION; PROTEIN INTERACTION MAPS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 84920911908     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S71677     Document Type: Article

References (87)

1. Ahmed HU. Prostate cancer: Time for active surveillance of intermediate-risk disease? Nat Rev Urol. 2013;10(1):6-8.
2. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. [homepage on the Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on November 7, 2014.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917.
4. Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet. 2012;380(9856):1840-1850.
5. Gunderson K, Wang CY, Wang R. Global prostate cancer incidence and the migration, settlement, and admixture history of the Northern Europeans. Cancer Epidemiol. 2011;35(4):320-327.
6. U.S. Cancer Statistics Working Group. [webpage on the Internet]. United States Cancer Statistics: 1999-2010 Incidence and Mortality Web-based Report. Atlanta, GA: 2013. Available from http://apps. nccd.cdc.gov/uscs/. Accessed November 7, 2014.
7. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252-271.
8. Cancer Research UK. [homepage on the Internet]. Cancer statistics report: Cancer incidence and mortality in the UK for the 10 most common cancers December 2013. Available from http://publications. cancerresearchuk.org/cancerstats/statsincidence/reporttop10incmort. html. Accessed November 7, 2014.
9. Klotz L. Nomogram for predicting survival in men with clinically localized prostate cancer who do not undergo definitive therapy. Nat Clin Pract Urol. 2008;5(7):362-363.
10. Albertsen P. Predicting survival for men with clinically localized prostate cancer: what do we need in contemporary practice? Cancer. 2008;112(1):1-3.
11. American Cancer Society. [webpage on the Internet]. Global cancer facts and figures. 2nd edition. Atlanta: 2011 Available from: http://www.can-cer.org/research/cancerfactsfigures/globalcancerfactsfigures/. Accessed November 7, 2014.
12. Saylor PJ. Prostate cancer: The androgen receptor remains front and centre. Nat Rev Clin Oncol. 2013;10(3):126-128.
13. Wen S, Niu Y, Lee SO, Chang C. Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death. Cancer Treat Rev. 2014;40(1):31-40.
14. Rodrigues DN, Butler LM, Estelles DL, de Bono JS. Molecular pathology and prostate cancer therapeutics: from biology to bedside. J Pathol. 2014;232(2):178-184.
15. Helfand BT, Catalona WJ. The epidemiology and clinical implications of genetic variation in prostate cancer. Urol Clin North Am. 2014; 41(2):277-297.
16. Fang YX, Gao WQ. Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene. 2014;33(2):135-147.
17. Fraser M, Berlin A, Bristow RG, van der Kwast T. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urol Oncol. Epub 2014 Apr 22.
18. Crawford ED, Ventii K, Shore ND. New biomarkers in prostate cancer. Oncology (Williston Park). 2014;28(2):135-142.
19. Barve A, Jin W, Cheng K. Prostate cancer relevant antigens and enzymes for targeted drug delivery. J Control Release. 2014;187C:118-132.
20. Zheng H, Kang Y. Multilayer control of the EMT master regulators. Oncogene. 2014;33(14):1755-1763.
21. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelialmesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178-196.
22. Nauseef JT, Henry MD. Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat Rev Urol. 2011;8(8):428-439.
23. Byles V, Zhu L, Lovaas JD, et al. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene. 2012;31(43):4619-4629.
24. Padhye S, Dandawate P, Yusufi M, Ahmad A, Sarkar FH. Perspectives on medicinal properties of plumbagin and its analogs. Med Res Rev. 2012; 32(6):1131-1158.
25. Subramaniya BR, Srinivasan G, Sadullah SS, et al. Apoptosis inducing effect of plumbagin on colonic cancer cells depends on expression of COX-2. PLoS One. 2011;6(4):e18695.
26. Nazeem S, Azmi AS, Hanif S, et al. Plumbagin induces cell death through a copper-redox cycle mechanism in human cancer cells. Mutagenesis. 2009;24(5):413-418.
27. Xu KH, Lu DP. Plumbagin induces ROS-mediated apoptosis in human promyelocytic leukemia cells in vivo. Leuk Res. 2010;34(5): 658-665.
28. Sun J, McKallip RJ. Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression. Leuk Res. 2011;35(10):1402-1408.
29. Shieh JM, Chiang TA, Chang WT, et al. Plumbagin inhibits TPA-induced MMP-2 and u-PA expressions by reducing binding activities of NF-kappaB and AP-1 via ERK signaling pathway in A549 human lung cancer cells. Mol Cell Biochem. 2010;335(1-2): 181-193.
30. Li YC, He SM, He ZX, et al. Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells. Cancer Lett. 2014; 344(2):239-259.
31. Sinha S, Pal K, Elkhanany A, et al. Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo. Int J Cancer. 2013;132(5):1201-1212.
32. Aziz MH, Dreckschmidt NE, Verma AK. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res. 2008; 68(21):9024-9032.
33. Powolny AA, Singh SV. Plumbagin-induced apoptosis in human prostate cancer cells is associated with modulation of cellular redox status and generation of reactive oxygen species. Pharm Res. 2008;25(9):2171-2180.
34. Abedinpour P, Baron VT, Chrastina A, Welsh J, Borgstrom P. The combination of plumbagin with androgen withdrawal causes profound regression of prostate tumors in vivo. Prostate. 2013;73(5): 489-499.
35. Ong SE, Mann M. Stable isotope labeling by amino acids in cell culture for quantitative proteomics. Methods Mol Biol. 2007;359:37-52.
36. Mann M. Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol. 2006;7(12):952-958.
37. Ong SE. The expanding field of SILAC. Anal Bioanal Chem. 2012; 404(4):967-976.
38. Wang R, Fang X, Lu Y, Wang S. The PDBbind database: collection of binding affinities for protein-ligand complexes with known threedimensional structures. J Med Chem. 2004;47(12):2977-2980.
39. Yang L, Luo H, Chen J, Xing Q, He L. SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome. Nucleic Acids Res. 2009;37(Web Server issue):W406-W412.
40. Yang L, Chen J, Shi L, Hudock MP, Wang K, He L. Identifying unexpected therapeutic targets via chemical-protein interactome. PLoS One. 2010;5(3):e9568.
41. Luo H, Chen J, Shi L, et al. DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemicalprotein interactome. Nucleic Acids Res. 2011;39(Web Server issue): W492-W498.
42. Huang da W, Sherman BT, Tan Q, et al. The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 2007; 8(9):R183.
43. Ong SE, Mann M. A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat Protoc. 2006;1(6): 2650-2660.
44. Lecoeur H. Nuclear apoptosis detection by flow cytometry: influence of endogenous endonucleases. Exp Cell Res. 2002;277(1):1-14.
45. Sunil C, Duraipandiyan V, Agastian P, Ignacimuthu S. Antidiabetic effect of plumbagin isolated from Plumbago zeylanica L. root and its effect on GLUT4 translocation in streptozotocin-induced diabetic rats. Food Chem Toxicol. 2012;50(12):4356-4363.
46. Wang CC, Chiang YM, Sung SC, Hsu YL, Chang JK, Kuo PL. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. Cancer Lett. 2008;259(1):82-98.
47. Shanware NP, Bray K, Abraham RT. The PI3K, metabolic, and autophagy networks: interactive partners in cellular health and disease. Annu Rev Pharmacol Toxicol. 2013;53:89-106.
48. Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005;16(8):797-803.
49. Wu WK, Coffelt SB, Cho CH, et al. The autophagic paradox in cancer therapy. Oncogene. 2012;31(8):939-953.
50. Ferreira CG, Epping M, Kruyt FA, Giaccone G. Apoptosis: target of cancer therapy. Clin Cancer Res. 2002;8(7):2024-2034.
51. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov. 2010;9(6):447-464.
52. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274-293.
53. Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol. 2010;7(4):209-219.
54. Preyat N, Leo O. Sirtuin deacylases: a molecular link between metabolism and immunity. J Leukoc Biol. 2013;93(5):669-680.
55. Montecucco F, Cea M, Bauer I, et al. Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience. Curr Drug Targets. 2013;14(6):637-643.
56. Keum YS, Choi BY. Molecular and chemical regulation of the Keap1 Nrf2 signaling pathway. Molecules. 2014;19(7):10074-10089.
57. Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401-426.
58. Hu X, Moscinski LC. Cdc2: a monopotent or pluripotent CDK? Cell Prolif. 2011;44(3):205-211.
59. Warfel NA, El-Deiry WS. p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol. 2013;25(1):52-58.
60. Yoon MK, Mitrea DM, Ou L, Kriwacki RW. Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem Soc Trans. 2012;40(5):981-988.
61. Carvajal LA, Manfredi JJ. Another fork in the road life or death decisions by the tumour suppressor p53. EMBO Rep. 2013;14(5): 414-421.
62. Settembre C, Fraldi A, Medina DL, Ballabio A. Signals from the lyso some: a control centre for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol. 2013;14(5):283-296.
63. Maes H, Rubio N, Garg AD, Agostinis P. Autophagy: shaping the tumor microenvironment and therapeutic response. Trends Mol Med. 2013;19(7):428-446.
64. Cannito S, Novo E, di Bonzo LV, Busletta C, Colombatto S, Parola M. Epithelial-mesenchymal transition: from molecular mechanisms, redox regulation to implications in human health and disease. Antioxid Redox Signal. 2010;12(12):1383-1430.
65. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem. 2001;276(42):38837-38843.
66. Bellot GL, Liu D, Pervaiz S. ROS, autophagy, mitochondria and cancer: Ras, the hidden master? Mitochondrion. 2013;13(3):155-162.
67. Dodson M, Darley-Usmar V, Zhang J. Cellular metabolic and autophagic pathways: traffic control by redox signaling. Free Radic Biol Med. 2013;63:207-221.
68. Kaminskyy VO, Zhivotovsky B. Free radicals in cross talk between autophagy and apoptosis. Antioxid Redox Signal. 2014;21(1): 86-102.
69. Hsu YL, Cho CY, Kuo PL, Huang YT, Lin CC. Plumbagin (5-hydroxy 2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinasemediated phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther. 2006;318(2):484-494.
70. Yang SJ, Chang SC, Wen HC, Chen CY, Liao JF, Chang CH. Plumbagin activates ERK1/2 and Akt via superoxide, Src and PI3-kinase in 3T3-L1 cells. Eur J Pharmacol. 2010;638(1-3):21-28.
71. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979;17(1):16-23.
72. Chen TR. Chromosome identity of human prostate cancer cell lines, PC-3 and PPC-1. Cytogenet Cell Genet. 1993;62(2-3):183-184.
73. Nupponen NN, Hyytinen ER, Kallioniemi AH, Visakorpi T. Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. Cancer Genet Cytogenet. 1998;101(1):53-57.
74. Ohnuki Y, Marnell MM, Babcock MS, Lechner JF, Kaighn ME. Chromosomal analysis of human prostatic adenocarcinoma cell lines. Cancer Res. 1980;40(3):524-534.
75. Beheshti B, Park PC, Sweet JM, Trachtenberg J, Jewett MA, Squire JA. Evidence of chromosomal instability in prostate cancer determined by spectral karyotyping (SKY) and interphase fish analysis. Neoplasia. 2001;3(1):62-69.
76. Ouyang DY, Xu LH, He XH, et al. Autophagy is differentially induced in prostate cancer LNCaP, DU145 and PC-3 cells via distinct splicing profiles of ATG5. Autophagy. 2013;9(1):20-32.
77. Feldman JL, Dittenhafer-Reed KE, Denu JM. Sirtuin catalysis and regulation. J Biol Chem. 2012;287(51):42419-42427.
78. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer. 2003;3(4):267-275.
79. Everley PA, Krijgsveld J, Zetter BR, Gygi SP. Quantitative cancer proteomics: stable isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research. Mol Cell Proteomics. 2004;3(7):729-735.
80. Deeb SJ, D’Souza RC, Cox J, Schmidt-Supprian M, Mann M. Super SILAC allows classification of diffuse large B-cell lymphoma subtypes by their protein expression profiles. Mol Cell Proteomics. 2012; 11(5):77-89.
81. Deeb SJ, Cox J, Schmidt-Supprian M, Mann M. N-linked glycosylation enrichment for in-depth cell surface proteomics of diffuse large B-cell lymphoma subtypes. Mol Cell Proteomics. 2014;13(1):240-251.
82. Lam YW, Mobley JA, Evans JE, Carmody JF, Ho SM. Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Proteomics. 2005;5(11):2927-2938.
83. Sardana G, Marshall J, Diamandis EP. Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture conditioned medium. Clin Chem. 2007;53(3):429-437.
84. Al-Ruwaili JA, Larkin SE, Zeidan BA, et al. Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis. Cancer Genomics Proteomics. 2010;7(2):93-103.
85. Skvortsov S, Schäfer G, Stasyk T, et al. Proteomics profiling of micro dissected low and high-grade prostate tumors identifies Lamin A as a discriminatory biomarker. J Proteome Res. 2011;10(1):259-268.
86. Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol. 2010;28(16):2777-2783.
87. Tian Q, Price ND, Hood L. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med. 2012;271(2):111-121.